Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126604 | 0.89 | BTK (0.57) | BTK | |
| SCHEMBL5127571 | 0.88 | BTK (0.57) | BTKCLK2 | |
| SCHEMBL3963393 | 0.87 | BTK (0.71) | BTKCLK2 | |
| SCHEMBL1322662 | 0.82 | BTK (0.86) | BTKCLK2 | |
| SCHEMBL3744839 | 0.81 | BTK (0.47) | BTKJAK2JAK3CLK2 | |
| SCHEMBL3963334 | 0.80 | BTK (0.60) | BTKCLK2 | |
| SCHEMBL4185338 | 0.80 | BTK (0.46) | BTKJAK2JAK1TYK2JAK3 | |
| SCHEMBL1323317 | 0.78 | BTK (0.71) | BTKJAK3CLK2 | |
| SCHEMBL5126629 | 0.78 | BTK (0.57) | BTK | |
| SCHEMBL4069996 | 0.78 | BTK (0.57) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2081923-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | BTK 1/4885JAK2 36/4885JAK1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.